This is, IMO, more of an issue for subsequent generations of HCV drugs—i.e. drugs not yet in clinical development. For the HCV drugs discussed on this board and the ones listed in #msg-28837898, the patent lives will run out before the “reservoir inflow” slows to an appreciable degree.
Market Data 
Markets 
AI
